*From the Authors*:

We thank Dr. Gueret and colleagues for their interest in our study ([@bib1]). They correctly point out that, although the SMART (Isotonic Solutions and Major Adverse Renal Events Trial) trial was registered before enrollment (NCT02444988, NCT02547779) and sepsis was prespecified as a subgroup of interest ([@bib2], [@bib3]), we did not separately register and publish a protocol for the current secondary analysis. Sepsis was prespecified as a subgroup of interest because we expected that patients with sepsis would be at high risk of acute kidney injury and death, receive larger-than-average volumes of intravenous crystalloid, and be physiologically susceptible to differences in crystalloid composition ([@bib4]). In-hospital mortality at 30 days, a secondary outcome of the SMART trial, was selected as the primary outcome of this secondary analysis to be consistent with other clinical trials in sepsis and because mortality is a common, patient-centered sepsis outcome.

Gueret and colleagues ask which vasopressors patients received in each group. At the time of enrollment, the percentage of patients in the balanced crystalloid group and saline group, respectively, receiving norepinephrine was 33.9% versus 31.6% (*P* = 0.35), vasopressin was 4.9% versus 3.5% (*P* = 0.19), phenylephrine was 2.9% versus 3.4% (*P* = 0.42), and epinephrine was 1.8% versus 1.5% (*P* = 0.71). The proportion of patients receiving each vasopressor each day was similar between groups on the first 5 days after ICU admission (*P* \> 0.29 for all), suggesting that differential use of vasopressors did not contribute to the differences in outcomes between groups.

We agree that fluid administered during initial sepsis resuscitation, before ICU admission, is a crucial consideration for randomized trials of fluid management in critical illness. A strength of the current analysis is that, for patients presenting to the emergency department or operating room, choice of crystalloid was controlled from initial presentation through ICU discharge---a key difference from other randomized trials studying crystalloid composition in critically ill patients ([@bib5]). Further research is needed to specifically evaluate the relative effects of crystalloid composition during initial resuscitation in the emergency department compared with fluid administration after ICU admission.

We also thank Dr. Hammond and colleagues for their meta-analysis combining the results of our SMART sepsis subgroup analysis with results from prior studies comparing balanced crystalloids to saline among patients with sepsis. In their meta-analysis, the point estimate favored balanced crystalloids over saline for all outcomes, and 95% confidence intervals demonstrated a statistically significant difference (major adverse kidney events and acute kidney injury) or approached a statistically significant difference (receipt of renal replacement therapy and death). We agree that, while awaiting additional data, using of balanced crystalloids rather than saline for adults with sepsis is reasonable.
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